Resveratrol for patients with chronic obstructive pulmonary disease: hype or hope?
Resveratrol for patients with chronic obstructive pulmonary disease: hype or hope?
复制标题
DOI：
10.1097/mco.0000000000000444
复制
发表时间：
2018-03
影响因子：
3.1
通讯作者：
Schols AMWJ
中科院分区：
文献类型：
--
作者：
Beijers RJHCG;Gosker HR;Schols AMWJ
慢性阻塞性肺疾病(COPD)是一种进行性肺部疾病，具有较高的肺外表现，并经常合并心血管疾病。白藜芦醇是一种食源性化合物，具有抗炎、抗氧化、代谢和心脏保护作用。因此，白藜芦醇可能改善COPD的肺和肺外病理。在这篇综述中，我们将评估关于白藜芦醇对肺损伤、肌肉代谢和心血管风险的影响的知识，并讨论白藜芦醇对COPD患者是炒作还是希望。实验模型显示，白藜芦醇治疗后，慢性阻塞性肺疾病的肺部炎症和氧化应激均有所减轻。白藜芦醇的这些有益的抗炎和抗氧化特性也可以间接改善COPD患者的骨骼肌和呼吸肌损害。最近在非COPD人群中的临床研究表明，白藜芦醇治疗后线粒体氧化代谢得到改善，这可能有利于COPD患者的肺和肌肉损害。此外，临床前研究表明白藜芦醇具有心脏保护作用，但临床研究结果尚不确定。白藜芦醇可能是一种有趣的治疗候选药物，可以对抗COPD特有的肺和肌肉损伤。然而，没有令人信服的证据表明白藜芦醇可以显著降低COPD患者的心血管风险。
Chronic obstructive pulmonary disease (COPD) is a progressive lung disease with a high prevalence of extrapulmonary manifestations and, frequently, cardiovascular comorbidity. Resveratrol is a food-derived compound with anti-inflammatory, antioxidant, metabolic and cardioprotective potential. Therefore, resveratrol might improve the pulmonary as well as extrapulmonary pathology in COPD. In this review, we will evaluate knowledge on the effects of resveratrol on lung injury, muscle metabolism and cardiovascular risk profile and discuss if resveratrol is a hype or hope for patients with COPD. Experimental models of COPD consistently show decreased inflammation and oxidative stress in the lungs after resveratrol treatment. These beneficial anti-inflammatory and antioxidant properties of resveratrol can indirectly also improve both skeletal and respiratory muscle impairment in COPD. Recent clinical studies in non-COPD populations show improved mitochondrial oxidative metabolism after resveratrol treatment, which could be beneficial for both lung and muscle impairment in COPD. Moreover, preclinical studies suggest cardioprotective effects of resveratrol but results of clinical studies are inconclusive. Resveratrol might be an interesting therapeutic candidate to counteract lung and muscle impairments characteristic to COPD. However, there is no convincing evidence that resveratrol will significantly decrease the cardiovascular risk in patients with COPD.